Novel Therapeutics in Glaucoma Management

Title:Novel Therapeutics in Glaucoma Management

Volume: 16 Issue: 7

Author(s): Claudio Bucolo*, Chiara Bianca Maria Platania, Filippo Drago, Vincenza Bonfiglio, Michele Reibaldi, Teresio Avitabile and Maurizio Uva

Affiliation:

• Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania,Italy

Keywords: Glaucoma, anti-glaucoma drugs, intraocular pressure, retinal ganglion cells, purinergic ligands, Rho kinase inhibitors, dopamine ligands, nitric oxide, histone deacetylase inhibitors.

Abstract: Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.

Objective: An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.

Results: In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.

Conclusions: The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.

Cite this article as:

Bucolo Claudio *, Platania Bianca Maria Chiara, Drago Filippo , Bonfiglio Vincenza , Reibaldi Michele, Avitabile Teresio and Uva Maurizio, Novel Therapeutics in Glaucoma Management, Current Neuropharmacology 2018; 16 (7) . https://dx.doi.org/10.2174/1570159X15666170915142727